VIKING THERAPEUTICS INC (1VKTX.MI) Fundamental Analysis & Valuation

BIT:1VKTX • US92686J1060

Current stock price

24.93 EUR
-0.3 (-1.17%)
Last:

This 1VKTX.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. 1VKTX.MI Profitability Analysis

1.1 Basic Checks

  • 1VKTX had negative earnings in the past year.
  • 1VKTX had a negative operating cash flow in the past year.
  • In the past 5 years 1VKTX always reported negative net income.
  • 1VKTX had a negative operating cash flow in each of the past 5 years.
1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VKTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -50.25%, 1VKTX is not doing good in the industry: 61.04% of the companies in the same industry are doing better.
  • The Return On Equity of 1VKTX (-56.28%) is better than 62.34% of its industry peers.
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROIC N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
1VKTX.MI Yearly ROA, ROE, ROIC1VKTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • 1VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1VKTX.MI Yearly Profit, Operating, Gross Margins1VKTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. 1VKTX.MI Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, 1VKTX has more shares outstanding
  • The number of shares outstanding for 1VKTX has been increased compared to 5 years ago.
  • There is no outstanding debt for 1VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1VKTX.MI Yearly Shares Outstanding1VKTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
1VKTX.MI Yearly Total Debt VS Total Assets1VKTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • 1VKTX has an Altman-Z score of 23.64. This indicates that 1VKTX is financially healthy and has little risk of bankruptcy at the moment.
  • 1VKTX's Altman-Z score of 23.64 is amongst the best of the industry. 1VKTX outperforms 94.81% of its industry peers.
  • There is no outstanding debt for 1VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.64
ROIC/WACCN/A
WACCN/A
1VKTX.MI Yearly LT Debt VS Equity VS FCF1VKTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 9.33 indicates that 1VKTX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 9.33, 1VKTX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • 1VKTX has a Quick Ratio of 9.33. This indicates that 1VKTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 9.33, 1VKTX belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.33
Quick Ratio 9.33
1VKTX.MI Yearly Current Assets VS Current Liabilites1VKTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. 1VKTX.MI Growth Analysis

3.1 Past

  • 1VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.00%.
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, 1VKTX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.67% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.4%
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%
EPS Next 5Y27.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
1VKTX.MI Yearly Revenue VS Estimates1VKTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
1VKTX.MI Yearly EPS VS Estimates1VKTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. 1VKTX.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1VKTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1VKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1VKTX.MI Price Earnings VS Forward Price Earnings1VKTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1VKTX.MI Per share data1VKTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A cheap valuation may be justified as 1VKTX's earnings are expected to decrease with -6.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1VKTX.MI Dividend Analysis

5.1 Amount

  • 1VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1VKTX.MI Fundamentals: All Metrics, Ratios and Statistics

VIKING THERAPEUTICS INC

BIT:1VKTX (2/16/2026, 7:00:00 PM)

24.93

-0.3 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)04-21
Inst Owners66%
Inst Owner ChangeN/A
Ins Owners2.17%
Ins Owner ChangeN/A
Market Cap2.82B
Revenue(TTM)N/A
Net Income(TTM)-359.64M
Analysts85.83
Price Target80.76 (223.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.26%
Min EPS beat(2)-51.32%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-29.95%
Min EPS beat(4)-51.32%
Max EPS beat(4)-17.21%
EPS beat(8)3
Avg EPS beat(8)-10.43%
EPS beat(12)5
Avg EPS beat(12)-6.84%
EPS beat(16)6
Avg EPS beat(16)-5.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.03%
PT rev (3m)-2.2%
EPS NQ rev (1m)-18.56%
EPS NQ rev (3m)-17.46%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-2.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-12.49%
Revenue NY rev (3m)-18.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.21
P/tB 5.21
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-3.22
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS4.79
TBVpS4.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.33
Quick Ratio 9.33
Altman-Z 23.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
EPS Next Y-19.4%
EPS Next 2Y-14.49%
EPS Next 3Y-6.42%
EPS Next 5Y27.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-70.61%
EBIT Next 3Y-20.98%
EBIT Next 5Y18.49%
FCF growth 1Y-217.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.44%
OCF growth 3YN/A
OCF growth 5YN/A

VIKING THERAPEUTICS INC / 1VKTX.MI Fundamental Analysis FAQ

What is the fundamental rating for 1VKTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to 1VKTX.MI.


What is the valuation status of VIKING THERAPEUTICS INC (1VKTX.MI) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (1VKTX.MI). This can be considered as Overvalued.


How profitable is VIKING THERAPEUTICS INC (1VKTX.MI) stock?

VIKING THERAPEUTICS INC (1VKTX.MI) has a profitability rating of 1 / 10.


How financially healthy is VIKING THERAPEUTICS INC?

The financial health rating of VIKING THERAPEUTICS INC (1VKTX.MI) is 8 / 10.


Can you provide the expected EPS growth for 1VKTX stock?

The Earnings per Share (EPS) of VIKING THERAPEUTICS INC (1VKTX.MI) is expected to decline by -19.4% in the next year.